Süss MicroTec Charts Ambitious Growth Path Through Strategic Investment

Süss MicroTec secures €115M loan to fund expansion, targeting €750M-€900M revenue by 2030. Near-term profitability dips as R&D and new product launches accelerate.

Süss MicroTec is executing a deliberate strategy of near-term investment to fuel long-term expansion, even at the expense of current profitability. The company’s clear objective is to achieve revenue between €750 million and €900 million by 2030, a goal management believes requires significant spending today.

Financial Firepower Substantially Increased

To fund this ambitious plan, the company has dramatically strengthened its financial foundation. It has secured a new syndicated loan facility worth €115 million, replacing an existing €56 million credit line nearly two years ahead of its maturity and on improved terms. This capital is earmarked for a comprehensive investment program.

Research and development spending is targeted to rise from 9% to 11% of revenue. A major portion of the funds, up to €45 million, is allocated for a new development center in Germany. Concurrent investments are being made at the production site in Zhubei, Taiwan. The product pipeline is also set to benefit, with ten new offerings—including AI chip modules and High Bandwidth Memory solutions—scheduled for launch within the next two years.

This aggressive spending has a tangible impact on current finances. Free cash flow swung to negative €22.6 million in 2025, a stark contrast to the positive €25.0 million recorded the previous year. Consequently, the dividend was reduced to €0.04 per share, down from €0.30 per share a year earlier.

Mixed Analyst Sentiment with a Bullish Tilt

For the current fiscal year 2026, company guidance forecasts revenue in a range of €425 million to €485 million, with an EBIT margin of just 8% to 10%. Lower capacity utilization and rising development costs are cited as primary pressures on the year’s earnings.

Despite this transitional phase, analyst consensus leans positive. Ten currently issued recommendations advise buying the stock, compared to only one sell recommendation. Following the company’s updated guidance, Deutsche Bank raised its price target from €58 to €62. Analyst Michael Kuhn characterized the revised outlook as a healthy adjustment, clearing the path for a strong recovery starting in 2027.

A dissenting view comes from DZ Bank. While analyst Armin Kremser increased his fair value estimate from €22 to €33, he maintained a sell recommendation. His concern is that the downturn in this transition year may prove more severe than initially anticipated.

The share price recently traded at €50.40, approximately 16% below its 52-week high of €60.25 reached in mid-March. The stock’s ability to resume its upward trajectory is seen as heavily dependent on order intake and margin trends in the second quarter. Analysts at Jefferies and Metzler point to stabilizing order patterns as a potential positive signal; order intake stabilized at €117.5 million in the fourth quarter of 2025, providing a foundation for the company’s transitional narrative.